← Back to Search

Arm 1: MM120 for Anxiety

Phase 3

Recruiting

Research Sponsored by Mind Medicine, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Are you willing to abstain from cannabis use for at least 12 weeks while you participate in the study?

Are you willing to use contraception throughout the study period?

Must not have

Have you used psychedelics in the past 2 years? e.g. LSD, MDMA, DMT, psilocybin, ayahuasca, mescaline, mushrooms, ecstasy

Have you or an immediate family member (child, sibling, parent) ever been diagnosed with Schizophrenia or Bipolar Disorder?

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Summary

The reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.

Eligible Conditions

Anxiety

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This study's timeline: screening for a total of 3 weeks, Double Blind Period for a total of 12 weeks, and an Open Label Extension for a total of 56 weeks.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

To evaluate the efficacy of a single dose of MM120 versus placebo on anxiety symptoms in adults with GAD

Secondary study objectives

To evaluate the efficacy of a single dose of MM120 versus placebo on additional measures of anxiety, functioning and quality of life in adults with GAD